, Tracking Stock Market Picks
Enter Symbol:
Immunogen, Inc. (IMGN) [hlAlert]

down 24.52 %

Immunogen, Inc. (IMGN) rated Outperform with price target $20 by Cowen

Posted on: Friday,  Aug 2, 2013  4:25 PM ET by Cowen

Cowen rated Outperform Immunogen, Inc. (NASDAQ: IMGN) on 08/02/2013, when the stock price was $18.92. Since
then, Immunogen, Inc. has lost 24.52% as of 01/08/2016's recent price of $14.28.
If you would have followed this Cowen's recommendation on IMGN, you would have lost 24.52% of your investment in 889 days.

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company's product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended to deliver potent chemotherapy specifically to a tumor. Each tumor-activated drug immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/2/2013 4:25 PM Buy
18.92 20.00
as of 12/13/2013
1 Week down  -4.07 %
1 Month down  -1.64 %
3 Months down  -19.14 %
1 YTD down  -24.10 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy